 |
Top 37 mRNA startups
Oct 12, 2024 | By Jason Kwon | 25 |
These startups develop microRNA and messengerRNA therapies (that regulate gene expression in human cells).
1
Country: USA | Funding: $135M
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
City Therapeutics is a biopharmaceutical company focused on developing next-generation small interfering RNAs.
2
Country: USA | Funding: $275.6M
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
3
Country: USA | Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
4
Country: Germany | Funding: $2.1B
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
CureVac is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA.
5
Country: Germany | Funding: $1.9B
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
6
Country: China | Funding: $1.4B
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics.
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics.
7
Country: USA | Funding: $480.9M
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
8
Country: USA | Funding: $449.5M
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
9
Country: USA | Funding: $442.6M
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
10
Country: USA | Funding: $433.5M
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
